{"id":155233,"date":"2021-02-15T03:13:45","date_gmt":"2021-02-15T08:13:45","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/equillium-presents-positive-interim-clinical-data-of-itolizumab-in-first-line-treatment-of-acute-graft-versus-host-disease-at-the\/"},"modified":"2024-08-18T11:43:40","modified_gmt":"2024-08-18T15:43:40","slug":"equillium-presents-positive-interim-clinical-data-of-itolizumab-in-first-line-treatment-of-acute-graft-versus-host-disease-at-the","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/equillium-presents-positive-interim-clinical-data-of-itolizumab-in-first-line-treatment-of-acute-graft-versus-host-disease-at-the.php","title":{"rendered":"Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line\u00a0Treatment of Acute Graft-Versus-Host Disease at the&#8230;"},"content":{"rendered":"<p><![CDATA[Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial\u00a0reduction in baseline corticosteroid use]]><\/p>\n<p>Follow this link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/02\/12\/2175125\/0\/en\/Equillium-Presents-Positive-Interim-Clinical-Data-of-Itolizumab-in-First-line-Treatment-of-Acute-Graft-Versus-Host-Disease-at-the-2021-Transplantation-and-Cellular-Therapy-Meetings.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line\u00a0Treatment of Acute Graft-Versus-Host Disease at the...\">Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line\u00a0Treatment of Acute Graft-Versus-Host Disease at the...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Follow this link: Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line\u00a0Treatment of Acute Graft-Versus-Host Disease at the... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/equillium-presents-positive-interim-clinical-data-of-itolizumab-in-first-line-treatment-of-acute-graft-versus-host-disease-at-the.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-155233","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/155233"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=155233"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/155233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=155233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=155233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=155233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}